Stifel Financial Corp Has $4.12 Million Holdings in Genmab A/S (NASDAQ:GMAB)

Stifel Financial Corp decreased its position in Genmab A/S (NASDAQ:GMAB) by 3.4% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 168,991 shares of the company’s stock after selling 5,936 shares during the quarter. Stifel Financial Corp’s holdings in Genmab A/S were worth $4,120,000 as of its most recent SEC filing.

A number of other large investors also recently made changes to their positions in the company. SG Americas Securities LLC grew its holdings in Genmab A/S by 22.8% in the 2nd quarter. SG Americas Securities LLC now owns 36,234 shares of the company’s stock valued at $911,000 after buying an additional 6,734 shares in the last quarter. Bank of New York Mellon Corp grew its stake in shares of Genmab A/S by 4.9% in the second quarter. Bank of New York Mellon Corp now owns 70,171 shares of the company’s stock valued at $1,763,000 after acquiring an additional 3,283 shares in the last quarter. Allspring Global Investments Holdings LLC increased its position in Genmab A/S by 123.0% during the second quarter. Allspring Global Investments Holdings LLC now owns 3,240 shares of the company’s stock worth $81,000 after acquiring an additional 1,787 shares during the period. Crossmark Global Holdings Inc. raised its stake in Genmab A/S by 11.4% in the 2nd quarter. Crossmark Global Holdings Inc. now owns 70,632 shares of the company’s stock worth $1,775,000 after purchasing an additional 7,242 shares in the last quarter. Finally, Ingalls & Snyder LLC boosted its holdings in Genmab A/S by 29.3% in the 2nd quarter. Ingalls & Snyder LLC now owns 229,700 shares of the company’s stock valued at $5,772,000 after purchasing an additional 52,117 shares during the period. Institutional investors own 7.07% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on GMAB shares. Truist Financial lowered their target price on shares of Genmab A/S from $53.00 to $50.00 and set a “buy” rating on the stock in a report on Monday, September 9th. Redburn Atlantic assumed coverage on Genmab A/S in a report on Tuesday, October 8th. They issued a “buy” rating for the company. BMO Capital Markets reissued an “outperform” rating and set a $48.00 target price (up from $46.00) on shares of Genmab A/S in a report on Friday, November 8th. Morgan Stanley restated an “equal weight” rating and issued a $31.00 price target on shares of Genmab A/S in a research report on Wednesday, September 11th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $50.00 price objective on shares of Genmab A/S in a research report on Wednesday, October 16th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $45.20.

Genmab A/S Stock Down 2.3 %

Genmab A/S stock opened at $20.17 on Monday. The stock has a market cap of $13.35 billion, a PE ratio of 19.58, a P/E/G ratio of 0.67 and a beta of 0.96. Genmab A/S has a 12-month low of $20.12 and a 12-month high of $32.88. The business’s 50-day moving average price is $22.15 and its two-hundred day moving average price is $25.05.

Genmab A/S (NASDAQ:GMAB) last announced its quarterly earnings results on Wednesday, November 6th. The company reported $0.29 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.32 by ($0.03). The company had revenue of $816.10 million for the quarter, compared to the consensus estimate of $838.20 million. Genmab A/S had a net margin of 23.49% and a return on equity of 14.64%. During the same period last year, the firm posted $0.47 earnings per share. As a group, analysts expect that Genmab A/S will post 1.28 earnings per share for the current year.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.